Bringing new technologies to light that improve quality, enable breakthroughs and simplify workflows is what we’re all about.

Halo Labs (formerly Optofluidics) is a venture-backed scientific instrumentation company that commercializes high throughput biopharmaceutical quality control tools using the latest optics, image processing and microfluidics.

Since being founded in the summer of 2010 by Professor David Erickson from Cornell University, Halo Lab's core mission has been to provide researchers with unprecedented insights into the particles present in their processes by leveraging our core scientific competency: novel optics. Over the years, Halo Labs has been the recipient of many prestigious awards, including Philadelphia’s Life Science Startup of 2012 and the Pittcon Silver Product Award; and has received over $6M in research grants from agencies including DARPA, FDA, NSF, NIST and NIH. Today, we dedicate our collective experience and novel technology to empower formulation researchers to learn more about the stability and quality of their biological drugs faster and with more accuracy than ever before.

Our institutional partners include BioAdvance, the Ben Franklin Technology Partners of South Eastern Pennsylvania and Broad Oak Capital Partners.

Executive Team

Robert Wicke


Robert has over 25 years of experience in life science instrumentation and product development. Before Halo, Robert was General Manager of Pall ForteBio responsible for growing the company with YOY growth of over 25% every year for four years. Robert was also the Senior VP of Instrumentation R&D at Pall Corporation and a corporate M&A member, helping acquire a variety of companies into Pall’s numerous markets. Before Pall, Robert was VP of Product Development and Operations for ForteBio from 2007 to 2012 where he helped exit the company to Pall Corporation for over $160M. Before that, Robert was at Molecular Devices Corporation, where he was Vice President of Product Development, being on the executive team that helped the $615M acquisition by MDS. Previously he was at Axon Instruments, Inc. for 13 years, as Vice President of Software Engineering, helping be the first private company to IPO on the Australian stock market, and then helped with the $140 million acquisition by Molecular Devices. Robert received a BA in Computer and Information Sciences and Mathematics from Drew University, NJ and an MS in Computer and Information Sciences from the University of Oregon.

Dr. Robert Hart

CTO, Founder

Robert manages the development of new technologies, and is one of Halo Labs’ founders. He’s served in many roles including directing product development, overseeing corporate and academic partnerships, leading the sale team, and also played a central role in bringing in over $6M of funding. Under Robert’s leadership, Halo Labs was selected for Life Science Startup of the year in 2012 by the Greater Philadelphia Alliance for Capital and Technologies. He attained his Biomedical Engineering doctorate from Drexel University under Dr. Moses Noh and Dr. Ryszard Lec, completed his post doc at the University of Pennsylvania under Dr. Haim Bau, and was also valedictorian of Drexel’s Class of 2010. Prior to Halo Labs, Robert worked in bioautomation for Genome Therapeutics and Eppendorf US (formerly Brinkmann).

Dr. Bernardo Cordovez

CSO, Founder

Bernardo leads application and business development, and is one of the Halo Labs’ founders. He has was previously CEO and CTO, and played a pivotal role in bringing over $6M in federal grant funding. Prior to starting Halo Labs, Bernardo was a Postdoctoral Associate at Cornell University, where he also obtained his M.S. and Ph.D. degrees in Mechanical Engineering. His wide range of technical experience includes particle analysis, detection and manipulation, drug delivery devices, microfluidics, nanophotonics and bioenergy production. In 2012, Bernardo was named one of Philadelphia’s top 30 under 30 entrepreneurs, the same year Halo Labs was named Philadelphia Life Science Startup of the year by the Greater Philadelphia Alliance for Capital and Technologies.

Rick Gordon

VP of Sales

Rick comes to Halo Labs with over 15 years of sales and sales management experience in start-up, emerging growth, and market-leading life science tools companies. Prior to joining Halo Labs, Rick held senior positions at Unchained Labs and Phasefocus, where he launched and built sales organizations and was a key member of the team that grew ForteBio into the bestselling label-free protein characterization platform on the market. Rick has also held sales positions at Molecular Devices, LabKey Software, and Pacific Biomarkers. Rick holds a B.S. in Biology from the University of Washington and an M.S. in Biology from the University of Maine.

Board of Directors

Prof. David Erickson

Co-Founder & Chairman

Dr. David Erickson is co-founder and Chairman of Halo Labs, Inc. In addition to his role at Halo Labs, he is the Sibley College Professor of Mechanical Engineering at Cornell University. Prior to joining Cornell, Dr. Erickson was a postdoctoral scholar at the California Institute of Technology and he received his Ph.D. from the University of Toronto. In recent years, Dr. Erickson has received the DARPA-MTO Young Faculty Award, the NSF CAREER Award, and the Department of Energy Early Career Award. In 2011, he was awarded the Presidential Early Career Award for Scientists and Engineers (PECASE) by President Obama. He was recently named a fellow of the Optical Society of America.

Dr. Shahram Hejazi

Board Member

Dr. Shahram Hejazi is a medical device/life science executive with general management experience in both early-stage ventures and large global companies. As a Venture Partner with BioAdvance, he is responsible for investments in device, diagnostics and imaging field. Previously, Dr. Hejazi was the President of Kodak’s life science division (now called Carestream Molecular Imaging), where he had global responsibility for R&D, manufacturing, operations, sales, marketing and service. Before Kodak, he was the CEO of Zargis Medical Corporation (an early-stage medical device company that spun off from Siemens), where he led the company’s efforts in areas ranging from raising capital and technology development to completion of several clinical trials, FDA approval and product launch. Prior to Zargis, Dr. Hejazi was the Head of the Strategic Business Development group at Siemens, responsible for identifying early-stage growth/investment opportunities and new business development in the medical field.

Dr. Joseph D. Keegan

Board Member

Dr. Keegan has more than 30 years of experience in life science businesses. As CEO at ForteBio, Inc., he led the Series C financing which raised $25M, established product development and sales strategies that resulted in 2007-11 compounded annual revenue growth of 45%, and exited the company through its sale to Pall Corporation, returning $160M to investors. During his 9-year tenure at Molecular Devices Corporation, Dr. Keegan grew the company’s revenues from $30M to $185M through internal growth and acquisitions. In 2007, he oversaw its acquisition by MDS Corporation for $615M. Dr. Keegan joined MDC from Becton Dickinson and Company, where he served as President of Worldwide Tissue Culture and Vice President, General Manager of Worldwide Flow Cytometry. Prior to Becton Dickinson, Dr. Keegan was Vice President of the Microscopy and Scientific Instruments Division of Leica, Inc. He currently serves on the Board of Directors of Arrayjet LTD, Bio-Techne (NASDAQ:TECH), Carterra, Interpace Diagnostics (NASDAQ:IDXG), Labcyte as Chairman and Nanomedical Diagnostics as Executive Chairman. Dr. Keegan holds a B.A. in Chemistry from Boston University and a Ph.D. in Physical Chemistry from Stanford University.

© Copyright 2018 - Halo Labs